When you begin treatment with a GLP-1 medication like Wegovy (semaglutide), Ozempic (semaglutide) or Mounjaro (tirzepatide), you always start at a very low dose and work your way up over several weeks or months. This is not arbitrary — it is a deliberate, evidence-based part of the treatment plan, designed to make the journey as safe and comfortable as possible.
What is dose titration?
Dose titration means starting at the lowest possible dose and increasing it at regular intervals until you reach the recommended maintenance dose. The approach is used with many types of medication, but it is particularly important for GLP-1 receptor agonists, because they affect the body in several ways simultaneously: they slow stomach emptying, influence satiety signals in the brain, and regulate blood sugar.
Why not start at the full dose straight away?
Clinical studies consistently show that gastrointestinal side effects from GLP-1 medications are directly dose-dependent: the higher the dose, the greater the risk of nausea, vomiting and diarrhoea. An analysis of the major STEP trials with semaglutide (published in the journal Obesity and cited in PMC) found that side effects occurred primarily during the dose-escalation phase and decreased significantly as the body adapted to each dose level.
A dedicated clinical study of tirzepatide dose-escalation regimens (PMC, 2020) showed that a slower, step-by-step escalation resulted in significantly fewer gastrointestinal side effects compared to rapid escalation — and this finding directly informed the slower titration schedule used in the pivotal SURPASS trials.
In short: your body needs time to adjust to the new hormonal signals, and dose titration is the way to give it that time.
Wegovy and Ozempic: Dose titration schedule
Semaglutide is injected once weekly. The titration schedule is designed to minimise side effects while the body adapts:
| Week | Dose (Wegovy) |
|---|---|
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1.0 mg |
| Weeks 13–16 | 1.7 mg |
| Week 17 onwards | 2.4 mg (maintenance) |
Ozempic follows the same titration pattern, but the maintenance dose is typically 1.0 mg or 2.0 mg depending on indication (diabetes vs. weight management) and individual response.
Important: The 0.25 mg and 0.5 mg doses are titration doses only. They are not intended to produce significant weight loss — their purpose is to let the body adapt. Most people begin to experience noticeable satiety and weight loss from around 1.0 mg.
Mounjaro: Dose titration schedule
Tirzepatide acts on two receptors (GLP-1 and GIP) and is titrated over 20 weeks to reach the maintenance dose:
| Week | Dose (Mounjaro) |
|---|---|
| Weeks 1–4 | 2.5 mg |
| Weeks 5–8 | 5 mg |
| Weeks 9–12 | 7.5 mg |
| Weeks 13–16 | 10 mg |
| Weeks 17–20 | 12.5 mg |
| Week 21 onwards | 15 mg (maintenance) |
The longer Mounjaro titration — 20 weeks — reflects the fact that tirzepatide is a dual-agonist with a stronger effect profile, and the body benefits from a more gradual introduction.
When does the medication start working?
A common question is: "Is the medication even doing anything at the low starting dose?"
The honest answer is: not fully — and that's by design. The initial doses are calibrated for tolerability, not maximum effect. Most people begin to experience meaningful satiety and initial weight loss from around 1.0 mg semaglutide and 5–7.5 mg tirzepatide. The full therapeutic potential is reached at the maintenance dose.
According to the STEP 1 trial published in the New England Journal of Medicine, participants on 2.4 mg semaglutide achieved an average weight loss of 14.9% over 68 weeks — and the majority of that loss happened after they reached the maintenance dose.
What to do if a dose increase is too tough
You don't have to tough it out at all costs. The FDA-approved prescribing information provides official options for adapting the titration:
- Delay a dose increase by up to 4 weeks if side effects are too disruptive. It is safe to stay at your current dose a little longer.
- Temporarily reduce the dose: if you cannot tolerate Wegovy 2.4 mg, you may drop back to 1.7 mg for a period and then try again.
- Talk to your doctor: for Mounjaro, your doctor can individualise the pace of titration.
Slowing the titration is not a failure — it is a clinically recognised approach. In the STEP 1 trial, only 4.5% of participants discontinued treatment due to gastrointestinal side effects. The vast majority reached the maintenance dose, even if some needed more time.
Practical tips during dose escalation
- Eat smaller portions — your stomach empties more slowly, so large meals can cause discomfort.
- Avoid fatty and fried foods around a dose increase — fat delays stomach emptying further.
- Inject in the evening so you sleep through the period when side effects are typically strongest.
- Stay well hydrated — dehydration worsens nausea.
- Track your clicks — remember that the number of clicks on your pen changes with every dose step.
Dose titration and click counting
Keep in mind that your pen delivers a different number of clicks at each dose step. A Wegovy pen set to 0.25 mg requires fewer clicks than one set to 2.4 mg. ClickDose helps you track exactly which dose you are on — and counts correctly at every stage of your titration, so you never have to guess what you are injecting.
Conclusion
Dose titration is not a compromise — it is evidence-based medicine. The gradual escalation protects you from unnecessary side effects and increases the likelihood that you will complete the full course of treatment and achieve the maximum therapeutic benefit. Be patient with the process, and speak openly with your doctor if any step feels difficult.
Sources
- FDA — Wegovy (semaglutide) prescribing information 2024
- FDA — Mounjaro (tirzepatide) prescribing information 2022
- NEJM — STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
- PMC — Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg
- PMC — Tirzepatide dose-escalation regimens: randomised clinical study (2020)
- Mayo Clinic — Semaglutide (subcutaneous): dosing and side effects
- Mayo Clinic — Tirzepatide (subcutaneous): dosing and side effects